Literature DB >> 22929410

Differential expression of pro-inflammatory cytokines in intra-epithelial T cells between trachea and bronchi distinguishes severity of COPD.

Greg Hodge1, Paul N Reynolds, Mark Holmes, Sandra Hodge.   

Abstract

Measuring T-cell production of intracellular cytokines by flow cytometry enables specific monitoring of airway inflammation and response to therapies in chronic lung diseases including chronic obstructive pulmonary disease (COPD). We have previously shown that T cells in the airways of ex- and current- smoker COPD patients and healthy smokers produce increased T-cell pro-inflammatory cytokines IFNγ and TNFα versus healthy controls. However, we could not differentiate between COPD groups and smokers due to a high degree of inter-patient variability. To address this limitation, we hypothesized that intraepithelial T cells obtained from brushings of trachea may serve as an ideal intra-patient control compared with cells obtained from left and right bronchi. Production of intracellular cytokines by intraepithelial T-cells obtained from trachea and right and left bronchi from 26 individuals with COPD (16 with GOLD I and 10 with GOLD II-III disease), 11 healthy controls and 8 smokers was measured by flow cytometry. There was a significant increase in intraepithelial T-cell IFNγ and TNFα in both right and left bronchi of GOLD II-III COPD patients compared to cells obtained from the trachea. There were no changes in T cell pro-inflammatory cytokines between the bronchi and trachea from control subjects, GOLD I COPD patients or healthy smokers. There was a significant negative correlation between increased intraepithelial IFNγ and TNFα in bronchial brushing T-cells compared with tracheal T-cells, and compared with FEV1. Monitoring intracellular intra-epithelial T-cell cytokine production in bronchial brushings using autologous tracheal brushings as controls provides improves the sensitivity of the technique. Therapeutic targeting of these pro-inflammatory cytokines and assessing the effects of drugs on immune reactivity has the potential to reduce lung inflammation caused by intra-epithelial T cells in COPD.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22929410     DOI: 10.1016/j.cyto.2012.07.022

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  6 in total

1.  CD4+ T-Cell Profiles and Peripheral Blood Ex-Vivo Responses to T-Cell Directed Stimulation Delineate COPD Phenotypes.

Authors:  Mustimbo E P Roberts; Brandon W Higgs; Philip Brohawn; Fernanda Pilataxi; Xiang Guo; Michael Kuziora; Russell P Bowler; Wendy I White
Journal:  Chronic Obstr Pulm Dis       Date:  2015-08-23

2.  COPD is associated with increased pro-inflammatory CD28null CD8 T and NKT-like cells in the small airways.

Authors:  Greg Hodge; Hubertus Jersmann; Hai B Tran; Patrick F Asare; Minnu Jayapal; Paul N Reynolds; Mark Holmes; Sandra Hodge
Journal:  Clin Exp Immunol       Date:  2022-05-12       Impact factor: 5.732

3.  Lung cancer is associated with decreased expression of perforin, granzyme B and interferon (IFN)-γ by infiltrating lung tissue T cells, natural killer (NK) T-like and NK cells.

Authors:  G Hodge; J Barnawi; C Jurisevic; D Moffat; M Holmes; P N Reynolds; H Jersmann; S Hodge
Journal:  Clin Exp Immunol       Date:  2014-10       Impact factor: 4.330

Review 4.  Immunodeficiency in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease.

Authors:  Sheling Xie; Kaifei Wang; Wei Zhang; Kun Xiao; Peng Yan; Yanqin Li; Wanxue He; Yuhan Zhang; Lixin Xie
Journal:  Inflammation       Date:  2018-10       Impact factor: 4.092

Review 5.  Emerging pharmaceutical therapies for COPD.

Authors:  Sowmya P Lakshmi; Aravind T Reddy; Raju C Reddy
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-07-21

6.  Targeting peripheral blood pro-inflammatory cytotoxic lymphocytes by inhibiting CD137 expression: novel potential treatment for COPD.

Authors:  Greg Hodge; Mark Holmes; Hubertus Jersmann; Paul N Reynolds; Sandra Hodge
Journal:  BMC Pulm Med       Date:  2014-05-15       Impact factor: 3.317

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.